Featured 13F manager
Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site · 2021 Q3–2026 Q2
- $21.7B
- 77 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeutics 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth Group 2.4%
- TMO - Thermo Fisher Scientific 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Book
| MSFT - Microsoft | 4.06% | Add +9.5% | 1,913,135 | $517.95 | $991M | +165,300 | +$122M |
| AON - AON PLC · CL A | 3.33% | Add +14.7% | 2,278,017 | $356.58 | $812M | +291,600 | +$104M |
| EXEL - Exelixis | 3.30% | Add +21.6% | 19,501,500 | $41.30 | $805M | +3,466,000 | +$99M |
| AMZN - Amazon | 3.15% | Add +15.5% | 3,505,700 | $219.57 | $770M | +471,100 | +$104M |
| NTRA - Natera | 2.80% | Reduce −11.8% | 4,253,452 | $160.97 | $685M | −568,357 | −$130M |
| RVMD - Revolution Medicines | 2.80% | Add +2.1% | 14,625,692 | $46.70 | $683M | +300,000 | +$156M |
| UNH - Unitedhealth Group | 2.67% | Add +16.6% | 1,886,500 | $345.30 | $651M | +269,200 | +$147M |
| TMO - Thermo Fisher Scientific | 2.50% | Reduce −9.0% | 1,258,241 | $485.02 | $610M | −125,000 | +$49M |
| HIMS - Hims & Hers Health · CL A | 2.50% | Add +30.8% | 10,746,852 | $56.72 | $610M | +2,533,271 | +$200M |
| DIS - Disney Walt | 2.44% | Add +6.7% | 5,198,968 | $114.50 | $595M | +324,700 | −$9M |
| CRM - Salesforce | 2.39% | Add +16.7% | 2,462,310 | $237.00 | $584M | +353,200 | +$8M |
| ADSK - Autodesk | 2.16% | Reduce −4.7% | 1,662,852 | $317.67 | $528M | −81,800 | −$12M |
| BSX - Boston Scientific | 1.90% | Add +19.2% | 4,746,557 | $97.63 | $463M | +765,500 | +$36M |
| GBTC - Ishares Bitcoin Trust ETF | 1.86% | Reduce −0.4% | 6,992,700 | $65.00 | $455M | −27,350 | +$25M |
| WAB - Wabtec | 1.81% | Add +68.6% | 2,205,098 | $200.47 | $442M | +896,900 | +$168M |
| BBIO - Bridgebio Pharma | 1.74% | Add +3.7% | 8,192,000 | $51.94 | $425M | +292,000 | +$84M |
| PTGX - Protagonist Therapeutics | 1.68% | Add +0.4% | 6,196,006 | $66.43 | $412M | +24,000 | +$70M |
| TRU - Transunion | 1.62% | Reduce −12.4% | 4,732,075 | $83.78 | $396M | −672,500 | −$79M |
| ARMK - Aramark | 1.41% | Reduce −30.3% | 8,996,202 | $38.40 | $345M | −3,903,499 | −$195M |
| INTU - Intuit | 1.36% | Reduce −9.1% | 488,088 | $682.91 | $333M | −48,570 | −$89M |
| K - Kellanova | 1.32% | New | 3,943,853 | $82.02 | $323M | +3,943,853 | +$323M |
| NDAQ - Nasdaq | 1.31% | Reduce −11.3% | 3,623,043 | $88.45 | $320M | −460,700 | −$45M |
| ADI - Analog Devices | 1.31% | Add +2.1% | 1,299,500 | $245.70 | $319M | +27,300 | +$16M |
| SCHW - Schwab Charles | 1.27% | Reduce −17.9% | 3,251,657 | $95.47 | $310M | −707,400 | −$51M |
| NYT - New York Times · CL A | 1.17% | Reduce −11.1% | 4,985,745 | $57.40 | $286M | −623,801 | −$28M |
| GOOG - Alphabet · CL C | 1.12% | Reduce −36.4% | 1,120,940 | $243.55 | $273M | −640,900 | −$40M |
| CBRE - CBRE Group · CL A | 1.04% | Reduce −23.5% | 1,616,038 | $157.56 | $255M | −497,100 | −$41M |
| MCK - Mckesson | 1.03% | Add +4.0% | 327,100 | $772.54 | $253M | +12,500 | +$22M |
| BEAM - Beam Therapeutics | 1.00% | Add +0.5% | 10,063,111 | $24.27 | $244M | +50,000 | +$74M |
| CRNX — | 0.98% | Add +24.2% | 5,770,098 | $41.65 | $240M | +1,124,000 | +$107M |
| ETHA - Ishares Ethereum Tr | 0.96% | New | 7,450,730 | $31.51 | $235M | +7,450,730 | +$235M |
| AGIO - Agios Pharmaceuticals | 0.95% | Add +0.2% | 5,781,066 | $40.14 | $232M | +13,600 | +$40M |
| V - VISA · CL A | 0.84% | Add +94.2% | 599,810 | $341.38 | $205M | +291,000 | +$95M |
| LQDA - Liquidia | 0.80% | Add +102.1% | 8,565,638 | $22.74 | $195M | +4,326,876 | +$142M |
| NSC - Norfolk Southn | 0.76% | New | 615,000 | $300.41 | $185M | +615,000 | +$185M |
| LNTH - Lantheus | 0.73% | Reduce −48.3% | 3,477,227 | $51.29 | $178M | −3,245,000 | −$372M |
| IQV - IQVIA | 0.73% | Reduce −75.6% | 938,551 | $189.94 | $178M | −2,912,800 | −$429M |
| WWD - Woodward | 0.64% | Reduce −32.0% | 621,973 | $252.71 | $157M | −292,700 | −$67M |
| MA - Mastercard · CL A | 0.50% | Add +40.6% | 213,771 | $568.81 | $122M | +61,700 | +$36M |
| CNTA - Centessa Pharmaceuticals | 0.43% | Reduce −4.4% | 4,331,318 | $24.25 | $105M | −198,000 | +$46M |
| TEVA - Teva Pharmaceutical Inds | 0.41% | New | 4,997,000 | $20.20 | $101M | +4,997,000 | +$101M |
| TNGX - Tango Therapeutics | 0.37% | Add +17.5% | 10,757,000 | $8.40 | $90M | +1,600,000 | +$43M |
| BBNX - Beta Bionics | 0.35% | Add +2.6% | 4,313,920 | $19.87 | $86M | +110,000 | +$25M |
| THC - Tenet Healthcare | 0.34% | Reduce −21.7% | 414,000 | $203.04 | $84M | −115,000 | −$9M |
| GRAL - Grail | 0.33% | Add +168.7% | 1,349,000 | $59.13 | $80M | +847,000 | +$54M |
| EHC - Encompass Health | 0.30% | Reduce −19.4% | 571,000 | $127.02 | $73M | −137,000 | −$14M |
| OSCR - Oscar Health · CL A | 0.28% | Add +146.5% | 3,639,000 | $18.93 | $69M | +2,163,000 | +$37M |
| ABVX - Abivax SA | 0.28% | New | 805,000 | $84.90 | $68M | +805,000 | +$68M |
| MARA | 0.27% | Add +338.3% | 3,660,000 | $18.26 | $67M | +2,825,000 | +$54M |
| MLYS - Mineralys Therapeutics | 0.26% | New | 1,673,053 | $37.92 | $63M | +1,673,053 | +$63M |
| VNET - VNET Group | 0.23% | Add +83.3% | 5,489,120 | $10.33 | $57M | +2,495,000 | +$36M |
| CDTX - Cidara Therapeutics | 0.20% | Add +154.0% | 508,000 | $95.76 | $49M | +308,000 | +$39M |
| Grayscale Coindesk Crypto | 0.19% | New | 851,193 | $55.90 | $48M | +851,193 | +$48M |
| Mr Cooper Group | 0.19% | Add +81.2% | 222,000 | $210.79 | $47M | +99,500 | +$29M |
| NKTR - Nektar Therapeutics | 0.18% | New | 791,000 | $56.90 | $45M | +791,000 | +$45M |
| CAH - Cardinal Health | 0.16% | Reduce −44.3% | 253,000 | $156.96 | $40M | −201,000 | −$37M |
| JOYY — | 0.15% | Reduce −20.7% | 625,000 | $58.61 | $37M | −162,906 | −$3M |
| FLUT - Flutter Entmt | 0.14% | Reduce −24.2% | 137,369 | $254.00 | $35M | −43,860 | −$17M |
| QURE - Uniqure | 0.14% | Add +3935.7% | 565,000 | $58.37 | $33M | +551,000 | +$33M |
| ASMB - Assembly Biosciences | 0.13% | New | 1,227,590 | $25.60 | $31M | +1,227,590 | +$31M |
| EDU — | 0.12% | Reduce −51.1% | 565,150 | $53.07 | $30M | −590,000 | −$32M |
| WAY - Waystar | 0.12% | Add +22.3% | 750,000 | $37.92 | $28M | +137,000 | +$3M |
| BIDU - Baidu | 0.11% | New | 207,996 | $131.77 | $27M | +207,996 | +$27M |
| DOCS - Doximity · CL A | 0.11% | New | 374,000 | $73.15 | $27M | +374,000 | +$27M |
| PRME - Prime Medicine | 0.11% | Add +533.3% | 4,750,000 | $5.54 | $26M | +4,000,000 | +$24M |
| ENTA - Enanta Pharmaceuticals | 0.10% | Hold | 2,122,262 | $11.97 | $25M | — | — |
| SGRY - Surgery Partners | 0.08% | Reduce −54.7% | 871,830 | $21.64 | $19M | −1,054,170 | −$24M |
| TYRA - Tyra Biosciences | 0.07% | Hold | 1,143,818 | $13.99 | $16M | — | — |
| INTC - Intellia Therapeutics | 0.04% | New | 607,200 | $17.27 | $10M | +607,200 | +$10M |
| SLNOEUR - Soleno Therapeutics | 0.04% | Add +2960.0% | 153,000 | $67.60 | $10M | +148,000 | +$10M |
| TECX - Tectonic Therapeutic | 0.04% | Reduce −25.0% | 640,000 | $15.69 | $10M | −213,050 | −$7M |
| Savara | 0.04% | Reduce −63.4% | 2,500,000 | $3.57 | $9M | −4,335,000 | −$7M |
| NVAX - Novavax | 0.03% | Add +4775.0% | 780,000 | $8.67 | $7M | +764,000 | +$7M |
| SDGR - Schrodinger | 0.02% | Reduce −74.3% | 284,000 | $20.06 | $6M | −822,000 | −$17M |
| Ishares Tr | 0.02% | New | 18,907 | $271.12 | $5M | +18,907 | +$5M |
| Allete | 0.02% | New | 75,000 | $66.40 | $5M | +75,000 | +$5M |
| TVRD - Tvardi Therapeutics | 0.01% | Hold | 43,225 | $38.97 | $2M | — | — |
| ALVO - Alvotech | 0.01% | Hold | 199,675 | $8.19 | $2M | — | — |
| MDGL - Madrigal Pharmaceuticals | 0.01% | Hold | 3,319 | $458.66 | $2M | — | — |
| SMC - Summit Midstream | 0.00% | Hold | 58,214 | $20.54 | $1M | — | — |
| BTSG - Brightspring Health Svcs | 0.00% | Hold | 22,000 | $29.56 | $650K | — | — |
| ALKS - Alkermes | 0.00% | Reduce −97.0% | 20,800 | $30.00 | $624K | −670,863 | −$19M |
| ROIV - Roivant Sciences | 0.00% | Hold | 37,000 | $15.13 | $560K | — | — |
| ARWR - Arrowhead Pharmaceuticals | 0.00% | Hold | 15,800 | $34.49 | $545K | — | — |
| WGS - Genedx · CL A | 0.00% | Reduce −98.5% | 5,000 | $107.74 | $539K | −321,677 | −$30M |
| GH - Guardant Health | 0.00% | Hold | 8,000 | $62.48 | $500K | — | — |
| ARQT - Arcutis Biotherapeutics | 0.00% | Hold | 26,000 | $18.85 | $490K | — | — |
| AXSM - Axsome Therapeutics | 0.00% | Hold | 4,000 | $121.45 | $486K | — | — |
| HQY - Healthequity | 0.00% | Reduce −98.4% | 5,000 | $94.77 | $474K | −314,800 | −$33M |
| INSM - Insmed | 0.00% | Hold | 3,000 | $144.01 | $432K | — | — |
| PGNY - Progyny | 0.00% | Hold | 18,000 | $21.52 | $387K | — | — |
| ONC - Beone Medicines | 0.00% | Hold | 1,100 | $340.70 | $375K | — | — |
| KRYS - Krystal Biotech | 0.00% | Hold | 2,000 | $176.53 | $353K | — | — |
| ACLXGBX - Arcellx | 0.00% | Hold | 4,000 | $82.10 | $328K | — | — |
| CGON - Cg Oncology | 0.00% | Hold | 8,000 | $40.28 | $322K | — | — |
| LIVN - Livanova | 0.00% | Hold | 6,000 | $52.38 | $314K | — | — |
| COR - Cencora | 0.00% | Hold | 1,000 | $312.53 | $313K | — | — |
| CAPR - Capricor Therapeutics | 0.00% | Hold | 41,000 | $7.21 | $296K | — | — |
| TVTX - Travere Therapeutics | 0.00% | Hold | 12,000 | $23.90 | $287K | — | — |
| GRFS - Grifols S A | 0.00% | Hold | 28,000 | $9.96 | $279K | — | — |
| ASND - Ascendis Pharma A/S | 0.00% | Hold | 1,400 | $198.81 | $278K | — | — |
| SBRA - Sabra Health Care Reit | 0.00% | Hold | 14,000 | $18.64 | $261K | — | — |
| SRRK - Scholar Rock | 0.00% | Hold | 7,000 | $37.24 | $261K | — | — |
| NUVL - Nuvalent | 0.00% | Reduce −98.0% | 3,000 | $86.48 | $259K | −147,000 | −$11M |
| MMSI - Merit Med Sys | 0.00% | Hold | 3,000 | $83.23 | $250K | — | — |
| COGT - Cogent Biosciences | 0.00% | Hold | 17,000 | $14.36 | $244K | — | — |
| GMED - Globus Med · CL A | 0.00% | Reduce −98.1% | 4,000 | $57.27 | $229K | −206,000 | −$12M |
| GEHC - GE HealthCare | 0.00% | Reduce −99.8% | 3,000 | $75.10 | $225K | −1,319,000 | −$98M |
| HR - Healthcare Rlty Tr · CL A | 0.00% | Hold | 12,000 | $18.03 | $216K | — | — |
| TWST - Twist Bioscience | 0.00% | Hold | 7,650 | $28.14 | $215K | — | — |
| GKOS - Glaukos | 0.00% | Hold | 2,600 | $81.55 | $212K | — | — |
| RARE — | 0.00% | Reduce −99.2% | 7,000 | $30.08 | $211K | −891,000 | −$32M |
| IMVT - Immunovant | 0.00% | Hold | 12,000 | $16.12 | $193K | — | — |
| PACB — | 0.00% | Hold | 135,000 | $1.28 | $173K | — | — |
| SNDX - Syndax Pharmaceuticals | 0.00% | Hold | 10,000 | $15.38 | $154K | — | — |
| ARDX - Ardelyx | 0.00% | Hold | 23,000 | $5.51 | $127K | — | — |
| DYN - Dyne Therapeutics | 0.00% | Hold | 10,000 | $12.65 | $127K | — | — |
| AM6 - Amicus Therapeutics | 0.00% | Hold | 16,000 | $7.88 | $126K | — | — |
| EVH - Evolent Health · CL A | 0.00% | Hold | 14,000 | $8.46 | $118K | — | — |
| ALT - Altimmune | 0.00% | Hold | 27,600 | $3.77 | $104K | — | — |
| CCCC - C4 Therapeutics | 0.00% | Hold | 28,000 | $2.22 | $62K | — | — |
| ANNA - Aleanna · CL A | 0.00% | Hold | 78,400 | $0.7885 | $62K | — | — |
| GERN - Geron | 0.00% | Hold | 43,000 | $1.37 | $59K | — | — |
| IOVA - Iovance Biotherapeutics | 0.00% | Hold | 26,000 | $2.17 | $56K | — | — |
| CGC - Canopy Growth | 0.00% | Hold | 30,000 | $1.46 | $44K | — | — |
| IRWD - Ironwood Pharmaceuticals · CL A | 0.00% | Hold | 13,000 | $1.31 | $17K | — | — |
Showing top 50 of 126 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| SPY - Spdr S&P 500 ETF Tr | 14.66% | Exit | 0 | $617.85 | $3.4B | −5,500,000 | −$3.4B |
| HESS | 3.47% | Exit | 0 | $138.54 | $804M | −5,805,000 | −$804M |
| ANSS - Ansys | 1.51% | Exit | 0 | $351.22 | $350M | −997,128 | −$350M |
| Verona Pharma | 0.74% | Exit | 0 | $94.58 | $171M | −1,810,000 | −$171M |
| AZEK · CL A | 0.74% | Exit | 0 | $54.35 | $171M | −3,141,400 | −$171M |
| Championx | 0.45% | Exit | 0 | $24.84 | $105M | −4,245,000 | −$105M |
| Verve Therapeutics | 0.18% | Exit | 0 | $11.23 | $41M | −3,612,000 | −$41M |
| ABT - Abbott Labs | 0.08% | Exit | 0 | $136.01 | $18M | −136,000 | −$18M |
| YMM - Full Truck Alliance | 0.08% | Exit | 0 | $11.81 | $18M | −1,550,598 | −$18M |
| PARA - Paramount Global · CLASS B | 0.07% | Exit | 0 | $12.90 | $17M | −1,346,151 | −$17M |
| Latam Airlines Group SA | 0.06% | Exit | 0 | $40.64 | $13M | −318,092 | −$13M |
| Helix Acquisition Ii · CL A | 0.03% | Exit | 0 | $10.65 | $6M | −600,000 | −$6M |
| VYGR - Voyager Therapeutics | 0.01% | Exit | 0 | $3.11 | $2M | −715,000 | −$2M |
| Janux Therapeutics | — | Exit | 0 | $23.10 | $1M | −48,000 | −$1M |
| Sage Therapeutics | — | Exit | 0 | $9.11 | $390K | −42,800 | −$390K |
| UTHR - United Therapeutics | — | Exit | 0 | $287.00 | $287K | −1,000 | −$287K |
| Springworks Therapeutics | — | Exit | 0 | $47.00 | $235K | −5,000 | −$235K |
| Akero Therapeutics | — | Exit | 0 | $53.25 | $213K | −4,000 | −$213K |
| BRKR - Bruker | — | Exit | 0 | $41.20 | $206K | −5,000 | −$206K |
| Third Harmonic Bio | — | Exit | 0 | $5.40 | $83K | −15,361 | −$83K |
| BYND - Beyond Meat | — | Exit | 0 | $3.47 | $66K | −19,000 | −$66K |
| Biodesix | — | Exit | 0 | $0.2812 | $36K | −128,000 | −$36K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs on this site · 2021 Q3–2026 Q2